News

Treatment with intravenous immunoglobulin (IVIG) during pregnancy may have helped ease symptoms of a fetal disorder in a girl born to a mother with myasthenia gravis (MG), according to a report from Germany. The woman’s firstborn had developed severe FARAD (or fetal acetylcholine receptor antibody-related disorder), which occurs…

Among people with myasthenia gravis (MG) living in Australia, women and seronegative patients — those whose tests fail to show MG-associated antibodies — reported a significantly higher disease toll in an online survey. This toll included a greater range of disease symptoms, earlier disease onset, longer waits…

Kyverna Therapeutics’ investigational cell therapy KYV-101 safely and effectively improved muscle strength and reduced fatigue in a woman with severe, hard-to-treat generalized myasthenia gravis (gMG), according to a case report. The patient was treated based on an individual case evaluation and outside of a clinical trial. “This groundbreaking…

A new under-the-skin injectable formulation of Vyvgart (efgartigimod alfa) has been approved by the European Commission for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — the most common type of MG-causing antibody. This subcutaneous (under-the-skin) formulation now can be…

Spanish-speaking patients living with myasthenia gravis (MG) — and their caregivers, family members, friends, and anyone else seeking to learn more about the rare neuromuscular disease — are invited to join in the next meeting of the Virtual International Spanish MG Support Group, or Miastenia Gravis Grupo de Apoyo,…

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Kyverna Therapeutics, giving the company the go-ahead to launch a Phase 2 clinical trial that will test its cell therapy, KYV-101, in people with myasthenia gravis (MG). This is the fifth IND…

The experimental treatment povetacicept (ALPN-303) may be more effective than current available treatments for myasthenia gravis (MG), according to preclinical data from Alpine Immune Sciences, which is developing the therapy. Specifically, povetacicept outperformed Vyvgart (efgartigimod) and off-label rituximab at reducing disease activity in a mouse model of the…

The U.S. Food and Drug Administration (FDA) has given Cabaletta Bio the go-ahead to launch a Phase 1/2 clinical trial testing its cell therapy CABA-201 in people with generalized myasthenia gravis (gMG). The upcoming trial is expected to enroll a dozen adults with gMG — six who are positive…

Both propofol and sevoflurane — two types of agents for anesthesia management — were found to be safe and effective when used without muscle relaxants in myasthenia gravis (MG) patients undergoing surgery to remove the thymus gland. These findings, involving patients at a hospital in Vietnam, highlight what researchers…

Negative emotions, a personality trait known as neuroticism, are more likely in people with myasthenia gravis (MG) than those without this disease, and may explain why these patients appear to be more liable to depression and anxiety, a study suggests. MG patients also scored lower than healthy adults for openness…